Literature DB >> 35783003

Single-level posterior lumbar fusions in patients with Ehlers Danlos Syndrome not found to be associated with increased postoperative adverse events or five-year reoperations.

Michael J Gouzoulis1, Alexander J Kammien1, Justin R Zhu1, Stephen M Gillinov1, Harold G Moore2, Jonathan N Grauer1.   

Abstract

Background: Ehlers Danlos Syndrome (EDS) is a rare connective tissue disorder that results from mutations in collagen genes. Potentially related to laxity and resultant degenerative changes, adult EDS patients may require posterior lumbar fusion (PLF). However, with low numbers, adequately powered outcome studies have been limited. The purpose of this study was to investigate risk of complications, readmissions and reoperations in adult patients with EDS following single-level PLF.
Methods: A retrospective study using the 2010 to 2020 MSpine Pearldiver dataset was performed. Adult patients undergoing single-level PLF (excluding any with anterior procedures) with and without EDS for which at least 90-day follow up was available were identified. Any cases performed for trauma, tumor, or infection were excluded.Single-level PLF EDS patients were then matched 1:4 with PLF non-EDS patients based on age, sex, and Elixhauser Comorbidity Index (ECI). Rates of ninety-day any, severe, and minor adverse events as well as readmissions were tabulated and compared with chi-square tests. Multivariate logistical regression was then performed (controlling for age, sex, and ECI).Reoperation surgeries over five years were assessed, Kaplan-Meier survival curves generated, and curves of those with and without EDS were compared with log rank test.
Results: In total, there were 170,100 single-level PLF case identified, of which 242 (0.14%) had EDS. After matching, there were 957 without EDS and 239 with EDS. On multivariate regression, there were no significant differences in 90-day any, severe, or minor adverse events, or readmissions (p>0.05 for each). Over five years, there were also not significant differences in rates of reoperation (p> 0.05). Conclusions: For EDS patients undergoing PLF, the current study identified similar 90-day adverse events and 5-year reoperation rates compared to those without EDS. These findings may be useful for patient counseling and surgical planning for those with this rare condition.
© 2022 The Author(s).

Entities:  

Keywords:  90-Day Complications; AAE, Any Adverse Events; CPT, Current Procedural Terminology; ECI, Elixhauser Comorbidity Index; EDS, Ehlers-Danlos syndrome; Ehlers Danlos; ICD, International Classification of Diseases; MAE, Minor Adverse Events; OR, Odds Ratio; PLF, Posterior lumbar fusion; Pearldiver; Posterior Lumbar Fusion; Readmissions; Reoperations; SAE, Severe Adverse Events

Year:  2022        PMID: 35783003      PMCID: PMC9241136          DOI: 10.1016/j.xnsj.2022.100136

Source DB:  PubMed          Journal:  N Am Spine Soc J        ISSN: 2666-5484


Introduction

Ehlers-Danlos syndrome (EDS) comprises a heterogenous group of rare, heritable disorders that affect connective tissue principally in the skin, bones and ligaments, and blood vessels, causing joint hypermobility, skin hyperextensibility, and tissue fragility [1]. These traits result directly from underlying collagen dysfunction, with most forms of EDS resulting from mutations in one of the genes encoding fibrillar collagens (types I, II, III, V, or XI) or enzymes involved in the synthesis of these collagens [2,3]. Owing to the collagen-related connective tissues defects causing hypermobility, patients with EDS may develop spinal issues [4]. This has received attention for those undergoing surgery for deformity early in life [5], [6], [7], [8], however limited attention has been given to adults EDS patients undergoing spinal procedures for degenerative etiologies. Limited case reports of patients undergoing varying surgeries have suggested that patients with EDS are at increased risk for bleeding and poor wound healing due to vascular abnormalities and tissue fragility [3,9,10]. It has been suggested that this risk may be contributed to by platelet function abnormalities, and the severity of the EDS has been suggested to correlated with bleeding risk [11]. In general, adult PLF procedures are associated high rates of success [12], but only limited case reports are available about spinal surgery in adult EDS patients [13,14]. Consequently, the current study was performed to examine adult EDS patients who underwent single-level PLF for demographic details, 90-day perioperative complications, and five-year surgery need for revision procedures relative to a matched non-EDS population.

Methods

Patient Sample

The present study made use of data from the 2010-2020 MSpine Pearldiver database. This large national insurance claims database contains both inpatient and outpatient information for over 1.15 million United States patients. The MSpine dataset contains data for commercially insured, Medicare, and Medicaid patients. It contains all information on any patient who underwent a spinal procedure in the Pearldiver database. Our Investigative Review Board found studies using this database to be exempt from review based on the de-identified nature of the data. Patients over eighteen years of age undergoing PLF with or without laminectomy were identified using the Current Procedural Terminology (CPT) codes 22612, 22630, and 22633. Patients who had a primary diagnosis code of fractures, infection, neoplasm, or were not in the database for at least 90 days following the surgery were excluded. Further, patients who had multi-level fusions or had concurrent anterior fusion were excluded. Patients with a diagnosis of EDS (any type) were then identified using the following International Classification of Diseases (ICD) codes: ICD-9-D-75683 and ICD10 codes ICD-10-D-Q796, ICD-10-D-Q7960, ICD-10-D-Q7961, ICD-10-D-Q7962, ICD-10-D-Q7963, and ICD-10-D-Q7969. Additional patient characteristics abstracted from the dataset included: age, sex, and ECI (Elixhauser Comorbidity Index, which was calculated by an algorithm included in the PearlDiver analysis package). Those without and with Ehlers Danlos Diagnosis were then matched 4:1 based on age, sex, and ECI to eliminate any significant differences in the variables between the two groups.

Postoperative outcomes

Perioperative outcomes were abstracted from the dataset based on ICD codes. Individual adverse events were aggregated into severe adverse events (SAE), minor adverse events (MAE), and any adverse event (AAE). SAEs included: surgical site infection, sepsis, dep vein thrombosis, pulmonary embolism, myocardial infection, cardiac arrest, and pancreatitis. MAEs included: pneumonia, urinary tract infection, acute kidney injury, wound dehiscence, transfusion, and hematoma. AAEs were noted if there was the occurrence of a serious or minor adverse event. Readmissions were separately noted. The rate of reoperation up to five-year survival after index surgery was then investigated. Reoperations were identified based on any subsequent surgery, including fusion, decompression, and/or revision or removal of instrumentation.

Statistical Analyses

Univariate comparison of non-matched patient characteristics (age, sex, and ECI) was performed with chi-square tests. Based on identified differences between the groups, 1:4 matching using age, sex, and ECI was performed, and chi-square tests were repeated. The rate of aggregated complications between the matched non-EDS and EDS groups were compared with univariate chi-square tests and multivariate logistical regression (controlling for age, sex, and ECI) to define odds ratio (OR) and 95% confidence interval (CI). Reoperation rates were determined using Kaplan-Meier analyses to determine timing and incidence. A log-rank (Mantel-Cox) test was performed to compare survival rate between the matched groups. Statistical analyses were performed using Pearldiver statistical software (Pearldiver, Colorado Springs, CO) and graphics and survival analyses were generated with Graphpad Prism 9 (GraphPad Software, San Diego, CA). Significance was set at p < 0.05.

Results

Study cohorts

Based on the inclusion criteria, 170,342 PLF patients were identified, of which 242 (0.14%) had EDS (Table 1). There were statistically significant differences between those without and with EDS for age (59.61 vs 44.33, p < 0.001) and sex (58.5% female vs 86.8% female, p < 0.01) but not ECI.
Table 1

Descriptive Characteristics of single-level PLF patients with and without Ehlers Danlos Syndrome

Non-Matched PLF GroupsMatched PLF Groups
Non-EDSEDSP -ValueNon-EDSEDSP - Value
Sample SizeN = 170100N = 242N = 957N = 239
Age (in years): Mean (SD)59.61(12.49)44.33(14.26)p < 0.00144.83(13.97)44.64(14.09)p = 0.87
SexFemaleMale99519(58.5%)70581(41.5%)210(86.8%)32(13.2%)p < 0.001829(86.6%)128(13.7%)207(86.6%)32(13.4%)p = 1.00
ECI:Mean (SD)4.01(3.25)4.76(3.37)p = 0.274.72(3.35)4.72(3.36)p = 1.00

Significance set to p <0.05.

Matched based on Age, Sex, ECI 4:1 Non-EDS (Ehlers Danlos Syndrome) to EDS

PLF = Posterior Lumbar Fusion

Descriptive Characteristics of single-level PLF patients with and without Ehlers Danlos Syndrome Significance set to p <0.05. Matched based on Age, Sex, ECI 4:1 Non-EDS (Ehlers Danlos Syndrome) to EDS PLF = Posterior Lumbar Fusion To address the inherent differences in the study cohorts, matching was done based on age, sex, and ECI. This resulted in 957 non-EDS patients and 239 patients in the EDS patients. Once this was done, there were no residual differences for age, sex, or ECI (Table 1).

Ninety-day adverse outcomes

The incidence of 90-day adverse events and readmissions are shown in Table 2. Even with the large national population, the incidence of several the individual adverse events were low. Notably, to adhere to privacy considerations, numbers of ten or less cannot be displayed and are indicated in the table with an asterisk.
Table 2

Univariate analyses of 90-day complications of Matched Groups

No Ehlers Danlos DiagnosisEhlers Danlos DiagnosisP - Value
Sample SizeN = 957N = 239
Any Adverse Events138 (14.4%)33 (13.8%)p = 0.92
Severe Adverse Events65 (6.8%)12 (5.0%)p = 0.38
Surgical Site Infection37 (3.9%)*
Sepsis11 (1.1%)*
Deep Vein Thrombosis11 (1.1%)*
Pulmonary Embolism**
Myocardial Infarction*0
Cardiac Arrest*0
Pancreatitis*0
Minor Adverse Events102 (10.7%)29 (12.1%)p = 0.49
Pneumonia16 (1.7%)*
Urinary Tract Infection49 (5.1%)18 (7.5%)
Acute Kidney Injury11 (1.1%)*
Wound Dehiscence21 (2.2%)*
Transfusion*0
Hematoma**
Readmissions91 (9.5%)28 (11.7%)p = 0.33

Significance set to p < 0.05

Matched for ECI, Age, Sex

An * indicates 10 or less patients

Univariate analyses of 90-day complications of Matched Groups Significance set to p < 0.05 Matched for ECI, Age, Sex An * indicates 10 or less patients Based on the above considerations, the univariate and multivariate statistical comparisons were done for the aggregated adverse events only (AAE, SAE, MAE, and readmission). Univariate analyses of these outcomes revealed no statistical differences (Table 2). Similarly, multivariate analyses controlling for age, sex, and ECI to address any residual differences after matching revealed no statistical differences (Table 3).
Table 3

Multivariate analyses of 90-day complications and readmissions of Ehlers Danlos patients

Odds Ratio95% Confidence IntervalP - Value
Any Adverse Event0.950.62 – 1.44p = 0.81
Severe Adverse Event0.990.38 – 1.37p = 0.32
Minor Adverse Event1.170.74 – 1.82p = 0.50
Readmissions1.260.79 – 1.97p = 0.31

Significance set to p < 0.05

Controlled for ECI, Age, Sex, EDS diagnosis

Multivariate analyses of 90-day complications and readmissions of Ehlers Danlos patients Significance set to p < 0.05 Controlled for ECI, Age, Sex, EDS diagnosis

Five- year reoperations

Patient were then tracked out to five years. By that time, the non-EDS groups had 49.6% still in the dataset and the EDS group had 40.6% still in the dataset. The rate of any subsequent surgeries within five years of both groups was compiled using a Kaplan Meier curve. There were 70 observed reoperations in the control group, for a survival rate of 86.6%, and 14 observed reoperations in the Ehlers Danlos group, for a survival rate of 87.0%. Based on these numbers, a Kaplan Meier curve was generated and there was no significant difference between the rate of survival between the two groups (p = 0.96, Fig. 1).
Fig. 1

The Kaplan-Meier curve showing five-year instrumentation survival following PLF comparing the two matched groups. Significance was determined with p < 0.05.

The Kaplan-Meier curve showing five-year instrumentation survival following PLF comparing the two matched groups. Significance was determined with p < 0.05. During the first ninety days following surgery, there was fourteen reoperations in control group, compared to six reoperations in the EDS group (Fig. 2). There was no significant difference in reoperation (p = 0.12). The most common reasons for reoperations in both the first ninety days and over five years for the EDS group was infection and complications with the implant.
Fig. 2

Discussion

Ehlers-Danlos Syndrome (EDS) is comprised of a set of rare genetic connective tissue conditions [15,16]. Based on resultant laxity and potential lumbar degenerative changes, patients with EDS may undergo PLF in their adult years, but the perioperative and long-term outcomes of PLF for EDS patients are not well understood. EDS patients were not found to have greater 90-day perioperative adverse events for any of the metrics assessed, including AAE, SAE, MAE, and readmission. This is consistent to the findings of Matur et al. who in a study of fifty-six pediatric deformity EDS patients, found that they do not have a greater risk of perioperative adverse events [17]. Nonetheless, this different from Rabenhorst et al. single-institution study of six pediatric EDS patients who found elevated adverse events in this patient population [18]. These findings are consistent with the few case reports available showing that adult EDS patients don't appear to have an increased risk of complications [13,14]. However, Uehara et al. reports concern for vascular fragility [14]. The large sample size of the current study makes it stand out from these prior reports [19]. Of additional note, one could question if the laxity inherent to the EDS population might predispose them to longer term adverse outcomes and/or revisions. However, five years revision rates were not found to be significantly different. As with any national database study, there are limitations inherent to the coding and conditions specific factors. However, as noted above, it is only with such tools that larger number can be assessed and studied. In fact, it is possible that some of the comparisons were not sufficiently powered for all analyses, but based on the numbers available, no significant differences could be detected. Additionally, EDS is a heterogenous disease with many subtypes, however due to a limit in ICD coding, it was not possible to perform adequate analysis on EDS subtypes. The study was limited in determining how patients obtained their EDS diagnosis. PLF is a heterogenous surgery, and that difference in how the surgery might have been performed cannot fully be accounted for. An additional limitation is that not there was attrition of patients from the dataset for the five-year follow up comparison, and this should be considered with interpretation of those results. Overall, based on the largest reported cohort of EDS patients undergoing single-level PLS, the current study found that adult EDS patients did not have any significant difference in 90-day adverse events, or 5-year reoperations compared to non-EDS patients following PLF. The literature on orthopaedic surgery in EDS patients is sparse. These findings may be useful for patient counseling and surgical planning for those with this rare condition.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  19 in total

Review 1.  Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.

Authors:  Brad Tinkle; Marco Castori; Britta Berglund; Helen Cohen; Rodney Grahame; Hanadi Kazkaz; Howard Levy
Journal:  Am J Med Genet C Semin Med Genet       Date:  2017-02-01       Impact factor: 3.908

2.  Posterior Spinal Fusion for Severe Spinal Deformities in Musculocontractural Ehlers-Danlos Syndrome: Detailed Observation of a Novel Case and Review of 2 Reported Cases.

Authors:  Masashi Uehara; Hiroki Oba; Terue Hatakenaka; Shota Ikegami; Shugo Kuraishi; Takashi Takizawa; Ryo Munakata; Tetsuhiko Mimura; Tomomi Yamaguchi; Tomoki Kosho; Jun Takahashi
Journal:  World Neurosurg       Date:  2020-08-19       Impact factor: 2.104

3.  Hemostatic abnormalities in patients with Ehlers-Danlos syndrome.

Authors:  A Artoni; A Bassotti; M Abbattista; B Marinelli; A Lecchi; F Gianniello; M Clerici; P Bucciarelli; S La Marca; F Peyvandi; I Martinelli
Journal:  J Thromb Haemost       Date:  2018-11-08       Impact factor: 5.824

4.  Natural history of spinal deformity in a patient with Ehlers-Danlos syndrome: case report with 20-year follow-up.

Authors:  Deepa Natarajan; Dino Samartzis; Yat-Wa Wong; Keith D K Luk; Kenneth M C Cheung
Journal:  Spine J       Date:  2011-06-02       Impact factor: 4.166

Review 5.  The Ehlers-Danlos syndrome, a disorder with many faces.

Authors:  A De Paepe; F Malfait
Journal:  Clin Genet       Date:  2012-03-15       Impact factor: 4.438

6.  A review of Ehlers-Danlos syndrome.

Authors:  Erin Miller; John M Grosel
Journal:  JAAPA       Date:  2020-04

7.  Posterior spinal fusion in patients with Ehlers-Danlos syndrome: a report of six cases.

Authors:  Brien Michael Rabenhorst; Sumeet Garg; J Anthony Herring
Journal:  J Child Orthop       Date:  2012-03-09       Impact factor: 1.548

Review 8.  A Systematic Review of Lumbar Fusion Rates With and Without the Use of rhBMP-2.

Authors:  Fabrizio Galimberti; Daniel Lubelski; Andrew T Healy; Timothy Wang; Kalil G Abdullah; Amy S Nowacki; Edward C Benzel; Thomas E Mroz
Journal:  Spine (Phila Pa 1976)       Date:  2015-07-15       Impact factor: 3.468

9.  Lumbar artificial disc replacement in Ehlers-Danlos syndrome: A case report and discussion of clinical management.

Authors:  Emily M Lindley; Brianna N Patti; Matthew Taylor; Evalina L Burger; Vikas V Patel
Journal:  Int J Spine Surg       Date:  2012-12-01

10.  Ehlers-Danlos syndrome.

Authors:  Farhana Tahseen Taj; Vijaya V Sajjan; Dolly Singh
Journal:  Indian Dermatol Online J       Date:  2014-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.